Sites and Stages of Autoreactive B Cell Activation and Regulation  by Shlomchik, Mark J.
Immunity
ReviewSites and Stages of Autoreactive
B Cell Activation and RegulationMark J. Shlomchik1,*
1Department of Laboratory Medicine and Department of Immunobiology, Yale University School of Medicine, New Haven, CT 06520, USA
*Correspondence: mark.shlomchik@yale.edu
DOI 10.1016/j.immuni.2007.12.004
B cells are essential for the development and pathogenesis of both systemic and organ-specific autoimmune
diseases. Autoreactive B cells are typically thought of as sources of autoantibody, but their most important
pathogenetic roles may be to present autoantigens to T cells and to secrete proinflammatory cytokines. A
rate-limiting step in the genesis of autoimmunity then is the activation of autoreactive B cells. Here, mecha-
nisms are discussed that normally prevent such activation and how they break down during disease. Inte-
grating classic work with recent insights, emphasis is placed on efforts to pinpoint the precursor cells for
autoantibody-secreting cells and the unique stimuli and pathways by which they are activated.Introduction
B cells are critical for promoting autoimmunity in a spectrum of
diseases, ranging from classical B cell-mediated autoimmune
diseases such as systemic lupus erythematosus (SLE) (Chan
et al., 1999b; Leandro et al., 2002; Sfikakis et al., 2005; Shlom-
chik et al., 1994) to rheumatoid arthritis (RA) (Edwards et al.,
2004) to diseases that until recently were thought to have no con-
tribution by B cells, including diabetes (Hu et al., 2007; Serreze
et al., 1996) and multiple sclerosis (Antel and Bar-Or, 2006). B
cells facilitate autoimmunity not just by secreting autoantibodies,
but also by presenting autoantigens to T cells and most likely by
secreting proinflammatory cytokines (Chan and Shlomchik,
1998; Chan et al., 1999a, 1999b; Harris et al., 2000; Wong
et al., 2004). As a consequence, targeting B cells has become
one of the most effective treatments of autoimmune disorders
to emerge in recent years, with the promise to modify disease
course (Sfikakis et al., 2005). This raises interest in understand-
ing how autoreactive B cells develop, how they are normally con-
trolled in health, and how they are activated in disease. A variety
of new insights have provided a clearer picture of these complex
processes, although there remain a number of unanswered
questions about regulation, the origins of autoreactive B cells,
and how they promote disease once activated in the course of
autoimmunity.
Self-Tolerance Mechanisms
B cell receptors are assembled via a stochastic process of join-
ing V, (D), and J region segments in developing B cell precursors.
Thus, the resulting receptor comprised of randomly selected H
and L chains has an unpredictable specificity that could include
ability to bind ‘‘self.’’ Indeed, it has been suggested that on
the order of 50% of B cell receptors (BCRs) carry unacceptably
high degrees of autoreactivity (Merrell et al., 2006; Nemazee,
1995; Novobrantseva et al., 2005; Souroujon et al., 1988;Warde-
mann et al., 2003). The concept of self-reactivity is complicated
by the fact that there is no discrete affinity cutoff, nor even a cat-
alog of relevant ‘‘self’’ molecules and epitopes. Rather, self-reac-
tivity can be defined either via in vitro binding assays with arbi-
trary definition of ‘‘positive’’ or in vivo by whether a B cell
carrying a putative self-reactive receptor is affected by interac-18 Immunity 28, January 2008 ª2008 Elsevier Inc.tion with the self-target. In vivo assessment is more physiologi-
cally relevant but harder to accomplish.
Initial studies suggested that the immune system dealt with
self-reactive B cells through either clonal deletion (abortion) or in-
activation (anergy) (Nossal and Pike, 1978, 1980). Subsequent
experiments have generally relied on BCR transgenic (Tg) or
site-directed transgenic mice, in which a preformed receptor
or receptor chain is introduced into the germline. In such mice
all, or a fraction of, developing B cells express the self-reactive
BCR and, depending on the system design, the effects of auto-
antigen recognition can be studied (Goodnow, 1992). A sum-
mary of the phenotypes observed in some of these systems is
given in Table 1. Classical studies of Nemazee and of Goodnow
confirmed that self-recognition could lead to clonal deletion and
clonal anergy, respectively (Goodnow et al., 1988; Nemazee and
Burki, 1989). It was later recognized that deletion occurs when
the cell has exhausted possibilities of further V gene rearrange-
ment (Gay et al., 1993; Tiegs et al., 1993). This continuing rear-
rangement process is termed receptor editing. After these initial
systems, a variety of analogous self-reactive BCR Tg and site-
directed transgenic models have been generated, oftentimes
via self-antigens of greater disease relevance (see below). These
have contributed to our understanding of regulation of self-
reactive cells and particularly to how this breaks down in disease
states.
The parameters that govern whether a cell becomes anergic,
undergoes receptor editing, or is deleted are not fully worked
out; however, avidity plays a role, with stronger signals promot-
ing the editing-deletion pathway and weaker signals permitting
anergic cell development (Fulcher et al., 1996; Hartley et al.,
1991; Hippen et al., 2005). B cells expressing receptors that
are weakly crosslinked by self will emerge from the bone marrow
(BM) and appear in the periphery (provided that their ligand
remains unavailable) as normal non-self-reactive B cells (Aplin
et al., 2003; Hannum et al., 1996; Liu et al., 2007a; Nemazee
et al., 1991; Shlomchik et al., 1993). This has been termed
‘‘clonal ignorance.’’
Although anergy is typically discussed as a discrete phenom-
enon, there are degrees of self-reactivity and hence degrees of
‘‘anergy’’ that may partially limit the responsiveness of a given
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engaged (Liu et al., 2007a; Merrell et al., 2006) and possibly the
degree of B cell activating factor of the TNF family (BAFF)-medi-
ated signals (Thien et al., 2004). A defining feature of anergy is the
reduced or absent ability to stimulate B cells via their Ag receptor
(Cooke et al., 1994; Goodnow et al., 1988). There may be other
defects that vary by system, including downregulation of sIgM,
resistance to LPS-mediated activation, shortened half-life in
vivo, and expression of an ‘‘immature-like’’ phenotype (Erikson
et al., 1991; Fulcher and Basten, 1994; Goodnow et al., 1988;
Liu et al., 2007a; Mandik-Nayak et al., 2000; Qian et al., 2001;
Roark et al., 1997; Santulli-Marotto et al., 1998). These individual
BCR Tg mice may reflect the spectrum of anergic B cells found
among a polyclonal repertoire in normal mice. This notion has re-
cently been supported elegantly in studies that recognized par-
allels between anergic cells with a BCR that crossreacts with
a nominal hapten, azophenylarsonate, and ssDNA, and a sub-
population of B cells in normal mice termed ‘‘An1’’ (Merrell
et al., 2006).
In addition to anergic and ignorant cells, the products of re-
ceptor editing can also appear in the periphery (Casellas et al.,
2001; Gay et al., 1993; Li et al., 2002b; Prak and Weigert,
1995; Tiegs et al., 1993). In some cases, editing will destroy
the autoreactive receptor, for example via a secondary rear-
rangement that replaces an in-frame Vk-Jk join with another
via an upstream Vk and a downstream Jk. However, in some
cases the second rearrangement could come on the other kappa
chromosome or at any one of the lambda loci, in which case
a cell with two productive rearrangements will result (Li et al.,
2001, 2002b; Liu et al., 2005). If the second receptor sufficiently
dilutes the autoreactivity of the initial HL pair, the cell will de-
velop, as either an anergic or an ignorant cell. L chains that
can negate the autoreactivity of pre-existing H chains are termed
‘‘editors.’’ Cells carrying dual receptorsmay have unique proper-
ties and it has been speculated that they could be important
precursors for autoantibodies generated during autoimmune
disease (Li et al., 2001; Liu et al., 2005). Thus, a variety of mech-
anisms ranging from elimination to functional inactivationof autoreactive B cells serves to shape the developing B cell
repertoire.
Phenotypes and Locations of Autoreactive B Cells
in the Periphery
Although B cells that survive BM self-tolerance mechanisms do
populate secondary lymphoid tissue, their phenotype, location,
and function can depend on the nature of their BCR. At least
some types of anergic B cells are found at the T cell-B cell bor-
der, consistent with their partially activated phenotype. Interest-
ingly, this location allows anergic B cells to interact with Ag-spe-
cific T cells (Cook et al., 1998). The fate of dual-receptor cells
may depend on the residual degree of self-reactivity. One type
of edited anti-DNA B cell differentiates into a marginal zone
(MZ) phenotype (Li et al., 2002b); this is likely due to residual
self-reactivity, consistent with data indicating that many MZ B
cells are positively selected by receptor crosslinking (Martin
and Kearney, 2002). Indeed, some autoreactive B cells with
specificity for the Smith (Sm) antigenic complex of ribonucleo-
proteins involved in mRNA splicing are positively selected into
the MZ and the related B-1 pool of B cells (Qian et al., 2001). Fi-
nally, ignorant B cells are found in follicles and possibly in theMZ
(Wang and Shlomchik, 1999).
What Is theState of Tolerance of Autoreactive Precursor
B Cells?
A major challenge has been to determine how the tolerance
mechanisms that shape the B cell repertoire break down during
disease. The precursor-product relationships that lead to autor-
eactive B cells in autoimmunity are only partially elucidated. Nat-
ural leakiness or genetically mediated failures in receptor editing
and/or anergy induction could lead to increased frequencies of
partially tolerized or nontolerized B cells in peripheral lymphoid
tissue. These could be precursors for activated autoreactive B
cells in systemic autoimmunity. Ignorant cells with latent autor-
eactivity could also be precursors for such cells.
Regardless of the origins of autoreactive cells, they must be
stimulated to divide and differentiate in order to generateTable 1. Mechanisms of Self-Tolerance Illustrated by BCR Transgenic Mice
Phenotype Example Description References
Deletion anti-MHCII Tg, anti-RBC, high-affinity
anti-IgG (RF) Tg (20.8.3)
lack of cells beyond the pre-B cell
stage in BM and in peripheral
lymphoid tissue
Murakami et al., 1992; Nemazee and
Burki, 1989; Wang and Shlomchik,
1998
Receptor editing anti-MHCII Tg, 3H9/Vk4 anti-dsDNA
Tg, 3H9 or 56R site-directed Tg, HEL
site-directed Tg with mHEL
cells express an endogenous VL rather
than the Tg-encoded one, or cells
express a limited repertoire of L chains
that veto autoreactivity
Gay et al., 1993; Hippen et al., 2005; Li
et al., 2001; Tiegs et al., 1993
Allelic inclusion anti-MHC II site-directed Tg, 3H9 56R cells coexpress an endogenous VL
with the Tg-encoded one, or cells
express two L chains, including one
that vetoes autoreactivity
Li et al., 2002b; Liu et al., 2005
Anergy anti-HEL Tg with sHEL, anti-DNA
(3H9/Vl1), anti-Sm Tg (2-12), ArsA1
cells have variably reduced sIgM
expression, shortened life span, and
localize to the T-B interface; variably
impaired response to LPS and
reduced response to BCR ligation
Erikson et al., 1991; Goodnow et al.,
1988; Merrell et al., 2006;
Santulli-Marotto et al., 1998
Clonal ignorance anti-IgG (RF) AM14 Tg, anti-La cells assume a normal follicular B cell
phenotype
Aplin et al., 2003; Hannum et al., 1996;
Shlomchik et al., 1993Immunity 28, January 2008 ª2008 Elsevier Inc. 19
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autoantibody-secreting clones recovered from diseased mice
and humans. These often contain somaticmutations in their V re-
gions and have switched isotype (Marion et al., 1989; Randen
et al., 1993; Shlomchik et al., 1987a, 1987b, 1990; Winkler
et al., 1992). In many cases, thesemutations are distributed non-
randomly, consistent with selection by autoantigen. Some of
these mutations increase affinity for self-antigens, particularly
in the case of anti-DNA, in which mutations to Arg and Asn often
result in higher affinity for DNA (Radic andWeigert, 1994). Finally,
autoantibodies in diseased animals frequently belong to large
clones that presumably result from chronic autoantigen-driven
proliferation (Marion et al., 1989; Shan et al., 1994; Shlomchik
et al., 1987a, 1987b, 1990). Together, these findings suggest
that autoreactive B cells are generated from responses to natu-
rally derived self-antigens that are either identical to or contain
the same epitopes as nominal self-antigens upon which the
in vitro detection assays (such as for DNA binding) were based.
Thus, there is reasonable understanding of how autoreactive B
cells are normally regulated as well as the nature of autoanti-
body-secreting cells found in disease. The major remaining
questions relate to how regulation fails in disease. What are
the autoantigens that break tolerance? At what microanantomi-
cal location(s) does the response occur? What are the precursor
cells and do the requirements for stimulation and/or the out-
comes depend on the nature of the precursor cells? What other
cell types are required to promote and/or regulate the initial
activation and differentiation of autoreactive B cells? What cyto-
kines and surface costimulatory receptors are critical for the
development of autoantibody-secreting cells?
Crossing BCR Tg Tolerance Models
to Autoimmune-Prone Strains
A primary approach to these questions has been to cross the Ig-
Tg systems that helped define B cell tolerance to strains of mice
genetically predisposed to develop systemic autoimmunity. The
concept behind these experiments is to observe autoreactive B
cell recruitment into the autoimmune response from the starting
point of a cell with a defined state of self-tolerance, as deter-
mined by the study of such cells on ‘‘normal’’ genetic back-
grounds. Table 2 is a summary of several of the systems that
were crossed onto autoimmune-prone backgrounds and a com-
parison of the phenotype in wild-type versus autoimmune-prone
strains.20 Immunity 28, January 2008 ª2008 Elsevier Inc.Initial studies used the HEL plus anti-sHEL and the anti-MHCI
models (Rathmell and Goodnow, 1994; Rubio et al., 1996). It was
important to study the Tg B cells in both the presence and ab-
sence of the autoantigen, which was possible in both of these
models. Because autoimmunity is accompanied by apparently
nonspecific B cell activation (Klinman and Steinberg, 1987),
this comparison allowed specific activation to be distinguished.
However, in both cases, there was little if any evidence that self-
tolerance was broken in the murine lupus model strain
MRL.Faslpr. Both clonal anergy and clonal deletion/editing
seemed to be intact, and there was little recruitment of these
self-reactive B cells into the antibody-secreting pool.
It is interesting to consider why these models did not reveal
loss of tolerance, and hence were not particularly useful in eluci-
dating this aspect of autoimmunity. One possible explanation is
that they were not specific for the autoantigens typically targeted
in systemic autoimmunity. Indeed, it is remarkable that, despite
the polygenic and variable nature of lupus in humans and mice,
three categories of autoantigens are immunodominant: DNA-as-
sociated, RNA-associated, and IgG (von Muhlen and Tan, 1995;
Witte et al., 2000). Recognizing this point, Weigert and
colleagues (Erikson et al., 1991; Gay et al., 1993; Shlomchik
et al., 1993), along with a number of other groups, subsequently
generated Tg and site-directed transgenic BCRs specific for dis-
ease-related autoantigens, such as DNA, IgG (the RF specificity),
and Sm (Pewzner-Jung et al., 1998; Santulli-Marotto et al.,
1998). Like the HEL and MHCI-specific models, in some cases
B cells specific for disease-related autoantigens demonstrated
altered development on normal genetic backgrounds,
including anergy, receptor editing, and deletion. The spectrum
and phenotype of anergy was variable, including developmental
arrest and degrees of resistance to LPS activation and exclusion
from follicular entry. To some extent, this seemed related to affin-
ity for self. At the other end of the spectrum, IgG-specific RF B
cells developed into normal follicular B cells and hence were
considered clonally ignorant on a BALB/c genetic background
(Hannum et al., 1996).
In contrast to the HEL and MHCI systems, B cells carrying Tg
and site-directed transgenic BCRs specific for disease-related
autoantigens, such as DNA, Sm, and IgG (the RF specificity),
were in some cases dysregulated in the context of autoim-
mune-prone genetic backgrounds (Hoyer et al., 2004; Li et al.,
2002a; Mandik-Nayak et al., 1999; Roark et al., 1995; Santulli-
Marotto et al., 2001; Wang and Shlomchik, 1999; William et al.,Table 2. Comparison of Self-Reactive B Cell Behavior in Normal and Autoimmune-Prone Genetic Backgrounds
BCR Tg Model Normal Phenotype Autoimmunity Model; Phenotype References
Anti-HEL, sHEL anergy MRL.Faslpr; anergy Rathmell and Goodnow, 1994
Anti-MHCI deletion, receptor editing MRL.Faslpr; deletion, receptor editing Rubio et al., 1996
Anti-ss and dsDNA (3H9 Tg
and 3H9 56R site-directed Tg)
anergy MRL.Faslpr; follicular entry and anti-DNA
production
Mandik-Nayak et al., 1999
receptor editing MRL.Faslpr and chronic GVHD; escape of
partially edited cells and altered editing
Chen et al., 2006; Li et al.,
2002a; Sekiguchi et al., 2002
Anti-IgG (RF) clonal ignorance MRL.Faslpr and B6/lpr; extrafollicular
B cell AFC response
Wang and Shlomchik, 1999;
William et al., 2002, 2005a
Anti-Sm developmental arrest
and anergy
MRL.Faslpr; anti-Sm secretion Santulli-Marotto et al., 2001
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antibodies in the serum and antibody-forming cells (AFCs) in
spleen. Thus, although BCR Tg mice specific for arbitrary anti-
gens remained tolerant on lupus-prone genetic backgrounds,
BCR Tg mice with a variety of disease-related specificities
demonstrated activation of these cells specifically in lupus-
prone mice. That autoantibody-secreting cells are generated
when these models are crossed onto lupus-prone genetic back-
grounds highlights two questions: what are the precursor cells
that initially are activated, and how has self-tolerance been
broken?
Are Central Tolerance Checkpoints Overcome
in Systemic Autoimmunity?
Genetic or acquired defects could lead to failure of receptor
editing or anergy induction. In some lupus-prone models, gross
defects in anergy induction have not been seen, in that cell pop-
ulations found anergic in normal mice still retain similar pheno-
types in autoimmune-prone mice (Rathmell and Goodnow,
1994). Yet, subtle defects have been observed (Mandik-Nayak
et al., 2000). In normal mice, expression of a Vh region that con-
fers anti-DNA specificity with most L chains leads to extensive
receptor editing with resultant rescue only of cells that express
a narrow spectrum of Vk regions that veto DNA binding (Li
et al., 2001; Radic et al., 1993). In MRL.Faslpr mice and also in
C57Bl/6 mice (which harbor some genes that enable autoimmu-
nity), there is a broader spectrum of L chains found either in sin-
gle sorted cells or hybridomas compared to those seen in normal
BALB/c mice (Chen et al., 2006; Li et al., 2002a; Sekiguchi et al.,
2006). These L chains are more permissive for DNA binding.
These studies raise the possibility of primary defects in the strin-
gency of self-tolerance in mice genetically predisposed to SLE.
There are two limitations to this interpretation. First, it is not
clear whether the emergence of partially edited cells is a primary
or a secondary defect. Evidence suggests that preexisting
autoantibodies—which block exposure of developing B cells to
autoantigens that, if not impeded by the autoantibodies, would
promote tolerance—could lead to secondary defects in central
tolerance (Fulcher et al., 1996; Wang and Shlomchik, 1998). In-
flammation can also influence early B cell development (Na-
gaoka et al., 2000; Ueda et al., 2004), and this in turn could
promote survival of autoreactive B cells. Second, the maturation
of partially edited B cells does not establish that these cells are
the precursors of autoantibody-secreting B cells, although this
is possible. In one model, many of the autoantibody-secreting
B cells no longer used the Vh site-directed transgenic, thus ob-
scuring the relationship (Li et al., 2002a). In a Vh site-directed
transgenic with very high affinity for DNA, spontaneous hybrid-
omas were recovered that used the Vh along with permissive L
chains; however, in these mice, there were very few B cells
and a very limited repertoire (Chen et al., 2006).
In the case of lupus-associated activation of anergic B cells
specific for DNA, it is easier to establish a precursor-product re-
lationship. In 3H9 H Tg mice, B cells carrying a l1 L chain react
with dsDNA. Such B cells generate serum autoantibody and
splenic AFCs on the MRL.Faslpr background (Mandik-Nayak
et al., 1999). However, DNA-reactive B cells in MRL.Faslpr mice
are no longer developmentally arrested or anergic, nor are they
excluded from follicles. Thus, the immune and genetic defectsin this background seem to short-circuit the self-tolerance
mechanisms themselves. Hence, the DNA-reactive B cells that
are recruited to become AFCs may derive from these B cells
that are no longer anergic rather than directly from anergic or
developmentally arrested cells. Nonetheless, both in vitro
(Noorchashm et al., 1999) and in vivo (Seo et al., 2002) experi-
ments demonstrate that if anergic anti-DNA B cells are
presented with T helper-related signals, they will proliferate
and differentiate, arguing that, particularly in the context of
strong T cell help, anergic B cells can be directly drawn into
autoimmune responses.
These results beg the question of the genetic basis for central
tolerance defects. Recently, insights have come from studying
particular central tolerance checkpoints in the context of genetic
loci that were isolated from a lupus-prone strain, NZM2410. The
genes and allelic variants that comprise these loci are being iso-
lated while at the same time the phenotypes they confer are be-
ing studied. Mice carrying the Sle1z allele have altered isoform
expression of Ly108 that is correlated with impaired induction
of anergy, possibly because of effects on BCR signaling (Kumar
et al., 2006). A very interesting recent finding in the NZM2410
model is that mice carrying the disease-associated Sle2z allele
have reduced receptor editing and altered differentiation of
autoreactive DNA-specific B cells, associated with increased
serum anti-DNA titers (Liu et al., 2007b).
Studies in humans have addressed this question by interrogat-
ing the B cell repertoire via single-cell sorting. In a series of
impressive studies, such cells were sorted from various stages
of B cell development, from immature through to memory cell,
and from normal and diseased (lupus and RA) subjects (Samuels
et al., 2005; Tiller et al., 2007; Wardemann et al., 2003; Yurasov
et al., 2005). The H and L chains were cloned and re-expressed
to reconstitute mAbs corresponding to the originally sorted cell.
Extensive panels assembled in this way were tested in a series of
binding assays that served as surrogates for either cell-constitu-
ent-, nuclear-, or poly-reactivity. In normal individuals, it was
found that such self-reactivity was progressively filtered out of
the B cell repertoire with cell maturation. However, this was
not the case in most lupus and RA patients, who incompletely
purged cells at both critical stages. In some cases, young lupus
patients were studied both prior to and after initial treatment
(Yurasov et al., 2005), eliminating the confounding effect of treat-
ment. The finding that, at least in some effectively treated
patients, the defects persisted suggested that these defects
were primary rather than secondary to the disease. Overall, al-
though multiple lines of evidence in mice and humans support
defects in central tolerance in lupus and other autoimmune syn-
dromes, more work is needed to determine which of these is
a primary versus a secondary defect and what the genetic basis
is for these defects.
Clonally Ignorant B Cells Generate Autoantibodies
Many studies have noted that the normal preimmune repertoire
includes B cells that react with self-constituents (McHeyzer-
Williams and Nossal, 1988; Souroujon et al., 1988; Wardemann
et al., 2003). Although the tolerance status of these self-reactive
cells has not always been clear, at least some of them can re-
spond to LPS. Self-reactivity of these cells has been determined
by in vitro assays, but such studies were not able to establishImmunity 28, January 2008 ª2008 Elsevier Inc. 21
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during autoimmune disease.
The AM14 BCR Tg mouse model, with B cells specific for
IgG2a (the RF specificity), has helped to elucidate role of clonally
ignorant cells. AM14 B cells can only recognize IgG2a of the ‘‘a’’
allotype. By crossing the BCR Tg onto Ig allotype congenic mice
of either ‘‘a’’ or ‘‘b’’ allotype (IgHa or IgHb), we created animals in
which a disease-related autoreactive B cell either could or could
not recognize a self-Ag. TheseBcells are not tolerized in a normal
BALB/c mouse (IgHa) and instead develop into phenotypically
and functionally typical follicular-type B cells that are indistin-
guishable in the BALB/c and IgHb allotype congenic CB.17
strains (Hannum et al., 1996; Shlomchik et al., 1993).
However, when the AM14 H or H+L Tg were crossed onto the
autoimmune-prone B6.Faslpr or MRL.Faslpr backgrounds, mice
developed large numbers of RF-secreting cells in the spleen
and elevated RF titers in serum (Wang and Shlomchik, 1999;
William et al., 2002, 2005b). Importantly, this response occurred
only on the IgHa autoimmune-prone strains and not the IgHb
ones, formally establishing that the responsewas driven by auto-
antigen. Thus, clonally ignorant cells do have the capacity to be
stimulated in vivo, despite the fact that the self-Ag signal is not
normally strong enough to enforce tolerance. The onset of this
spontaneous autoreactive B cell response was stochastic, with
an increasing fraction of mice with high degrees of RF B cell
activation with age (William et al., 2005a). This pattern of onset
indicated specific triggers—whether environmental, develop-
mental, or relating to other events in the body such as Ag avail-
ability—that initiate the response were operating, opening the
possibility of identifying them by means of this system. In any
case, these results establish directly that clonally ignorant cells
can be the precursors for disease-related autoantibodies.
Contributions of Extrafollicular and Germinal Center
Pathways to Autoreactive B Cell Responses
Studies of autoreactive B cell activation in lupus-prone animals
raised several questions. First, could the stage and site of toler-
ance breakdown be isolated? Second, what are the triggers for
this breakdown and why was it observed more readily in the
DNA-, RNA-, and IgG-specific (i.e., disease-related) models
than in the synthetic HEL- and MCHI-specific models?
Several themes have emerged from work in all of these sys-
tems. The first is that in some contexts, autoreactive responses
bypass the GC reaction. Seminal work with non-Tg systems had
already identified the T cell zone as an area of B cell activation
and AFC localization for autoreactive B cells in MRL.Faslpr
mice (Jacobson et al., 1995). In the RF system, we showed
that the spontaneous response in the spleen does not involve
the GC and instead proceeds at extrafollicular sites that are sim-
ilar to the location of T-independent responses and the AFC
phase of T-dependent responses (William et al., 2002). RF B cells
were observed to proliferate and differentiate into plasmablasts
at the border of the T zone and red pulp, in the marginal sinus-
bridging channels of the spleen. Figure 1 diagrams the cellular
interactions of the extrafollicular reaction, highlighting the cell-
interaction molecules that might govern this process. The anti-
DNA response in lupus-prone mice has not been as extensively
studied at the histologic level, but available data indicate that it
too does not proceed via the GC. Instead, DNA-specific (l1
+) B22 Immunity 28, January 2008 ª2008 Elsevier Inc.cells in 3H9 MRL.Faslpr mice are found in the outer T zone as
well as the T zone-red pulp border (Mandik-Nayak et al., 1999;
Seo et al., 2002).
The dominant role of the extrafollicular response for autoreac-
tive specificities such as RF and anti-DNA is somewhat surpris-
ing, because the AFCs secreting these autoantibodies have
many somatic mutations and have undergone affinity matura-
tion, clonal expansion, and isotype switch. Classically, somatic
mutation in particular has been thought restricted to the GC.
By microdissection of small clusters of B cells at extrafollicular
sites, we found that V region mutation does occur outside the
GC in this response (William et al., 2002). Furthermore, histologic
and FACS studies demonstrated two populations of B cells par-
ticipating in the RF response, both of whichwere rapidly dividing.
CD22hiCD44hi cells were not secreting Ab, but appeared to be
the precursors of CD22loCD44bright cells that did secrete Ab (Wil-
liam et al., 2005b). The latter cells had the appearance of plasma-
blasts and were also rapidly undergoing apoptosis, indicative of
a short-lived compartment. Both CD22hi and CD22lo cells con-
tained somatically mutated V regions.
There is evidence for extrafollicular responses and short-lived
plasmablasts in other models of lupus. A majority of AFCs in
spleens of NZB/W mice are short lived; these include anti-DNA
AFCs (Hoyer et al., 2004). Similarly, the histologic appearance
of the anti-DNA response generated by a parent / F1
‘‘GVHD’’ manipulation that generates a lupus-like response is
also consistent with an extrafollicular response (Sekiguchi
et al., 2002). Mice overexpressing BAFF via a Tg have autoimmu-
nity accompanied by large numbers of AFCs in splenic red pulp
and mesenteric LN medullary cords (Mackay et al., 1999). Lupus
patients, particularly when undergoing a flare, demonstrate ele-
vated frequencies of plasmablast-like cells in PBL (Arce et al.,
2001; Jacobi et al., 2003).
Despite the predominance of the extrafollicular reaction in
anti-DNA and RF B responses in spleens of MRL.Faslpr mice,
this does not exclude a role for GCs for other specificities and
in other genetic contexts. GCs have been reported to be numer-
ous in several autoimmune-prone strains of mice, though
whether they contain autoreactive B cells and whether they are
responsible for autoantibodies was not determined, nor was
a complete survey of ‘‘normal’’ strains performed (Luzina et al.,
2001). Disregulation of entry of autoreactive B cells into GCs
has been observed in lupus patients as well (Cappione et al.,
2005). In BAFF-Tg mice, plasmablasts are accompanied by
GCs as well (Mackay et al., 1999); recent evidence suggests
that the extra-GC pathway may be most important (Groom
et al., 2007). Though the extrafollicular plasmablast pathway is
emerging as a primary site and mechanisms by which disease-
related autoantibodies are generated (Weisel et al., 2007),
more needs to be known about the precise sites and pathways
used to generate various specific autoantibodies in lupus and
other autoimmune diseases.
What Are the Rules that Select and Direct
Autoimmune Responses?
That there are at the least two pathways for the activation of
autoreactive B cells in vivo, and that there are most likely at least
two types of precursor B cell (anergic and ignorant), raises
further questions: what controls the locus of activation, what
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different sites, and what are the consequences of extrafollicular
B cell activation—do memory cells form via this pathway? More
proximally, are there different outcomes or activation re-
quirements depending on whether the precursor cell is anergic
or ignorant? To a large degree, the answers to these questions
are not in, but it is worthwhile to integrate some recent studies
and to propose some ideas about how the responses are
regulated.
Figure 1. The Extrafollicular Pathway of Autoreactive B Cell
Activation
Shown is a putative pathway by which autoreactive plasmablasts develop in
the marginal sinus-bridging channels at the T zone-red pulp border. Most of
the details of this process have not yet been worked out, so this scheme
should be considered speculative. B cells are in blue, T cells in red, and DCs
in green. Molecules expressed by each cell type that are likely to play key roles
in activation and differentiation at each site are listed, with molecules that
receive signals on the cell in bold. (1) Most likely the response initiates with
antigen recognition and possibly T cell-B cell interaction at the T-B border,
as occurs in a variety of B cell immune responses. Notably, CD22+ activated
RF B cells are seen at this site during the spontaneous RF response in autoim-
mune MRL.Faslpr mice. Activation requires BCR recognition of Ag as well as
TLR7 or TLR9 signaling in the case of anti-RNA, anti-DNA, or RF B cells. T-B
crossactivation via various costimulatory molecules may also take place. (2)
Activated B cells presumably migrate to the T zone-red pulp border where
they continue to proliferate and differentiate into plasmablasts (eccentric cells
with nuclei shown). Some of these cells contact T cells and thus there may be
continued T cell stimulation or regulation of the process. Others are in contact
with DCs, which may provide rate-limiting help for plasmablast survival and
also secrete factors such as BAFF and APRIL that promote plasmablast devel-
opment and survival. (3) Whether memory B cells, which can recirculate into
the B zone, are generated via this pathway is unknown, as suggested by the
question mark.Roles of Toll-like Receptors, T Cells, and Other Stimuli
in Accounting for the Specificities and Nature
of Autoantibody Responses
Although MRL.Faslpr mice, particularly when aged, have few
GCs in spleen (Luzina et al., 2001; Masuda and Kasajima,
1999), RF B cells in MRL.Faslpr or BALB/c mice can readily be
recruited to GC responses by immunization with T-dependent
antigens (William et al., 2002; Herlands et al., 2007). Thus, RF
B cells are not inherently incapable of a GC response, nor are
MRL.Faslpr mice inherently unable to support one. These results
instead suggest that the stimulus itself influences the outcome.
The T-dependent RF antigens were comprised of IgG2a com-
plexed with foreign proteins such as KLH or CGG, which pre-
sumably recruited T help. In contrast, the physiologic antigen
for the spontaneous RF B cell immune response in MRL.Faslpr
mice has been unclear. In vitro experiments showed that RF B
cells are potently stimulated to proliferate by naturally occurring
immune complexes (ICs) in the serum of MRL.Faslpr mice. More-
over, IgG2a chromatin Abs, which complex with abundant chro-
matin found in culture supernatants (Rifkin et al., 2000), are po-
tent stimuli. Because chromatin autoantibodies are abundant
in MRL.Faslpr and many other lupus-prone mice and patients,
we hypothesized that these may be an important or dominant
trigger for in vivo RF B cell activation. Indeed, the stochastic on-
set of RF B cell activation in AM14 TgMRL.Faslpr mice correlated
with the presence of increased concentration of IgG2a chroma-
tin Abs in the same mouse (William et al., 2005a). Recently, we
tested this in vivo by infusing IgG2a chromatin mAbs in AM14
Tgmice. Indeed, this resulted in a robust extrafollicular response
but no RF GC response (Herlands et al., 2007).
These data have implications for both how RF responses are
triggered and also the control and initiation of the extrafollicular
pathway. One connection is with Toll-like receptor costimulation.
In vitro stimulation of RF B cells with chromatin-containing ICs
absolutely requires MyD88 signaling (Leadbetter et al., 2002).
Subsequently, it was shown that TLR9 and/or TLR7 were trans-
ducing this signal in the B cell, along with signals via the BCR
(Lau et al., 2005; Viglianti et al., 2003). Notably, although first
identified for RFs, this same paradigm should apply to activation
of anti-DNA B cells, and evidence in vitro supports this (Viglianti
et al., 2003). Similarly, RNA-specific B cells are activated by their
autoantigen in a TLR7-dependent fashion in vitro (Lau et al.,
2005). These in vitro studies highlighted specific TLRs with
potential specificity for lupus-related self-antigens as major de-
terminants of the characteristic profile of lupus autoantibodies,
thus addressing a long-standing mystery of why certain autoan-
tigens are preferred targets in SLE.
The idea that TLR signals are important for activation of clas-
sical lupus autoantibody responses has been tested directly in
vivo by crossing TLR7, TLR9, and MyD88 null alleles onto auto-
immune-prone backgrounds (Christensen et al., 2005, 2006; Lau
et al., 2005; Sadanaga et al., 2007). Indeed, anti-chromatin
responses depended on TLR9 (Christensen et al., 2005, 2006;
Ehlers et al., 2006), and anti-Sm responses were found to be
TLR7 dependent (Christensen et al., 2006). A spontaneousmuta-
tion that duplicated TLR7 onto the Y chromosome also promoted
anti-RNA and disease when crossed onto a permissive genetic
background (Pisitkun et al., 2006; Subramanian et al., 2006).
On a mixed genetic background that included MRL genes,Immunity 28, January 2008 ª2008 Elsevier Inc. 23
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anti-Sm (Lau et al., 2005). The dependence of ANA on MyD88
was recently confirmed on a more fully backcrossed MRL.Faslpr
background (Sadanaga et al., 2007; our unpublished data).
There are many cell types, including DCs, that can both
respond to TLR signals delivered via chromatin-containing ICs
(Boule et al., 2004) and influence autoantibody generation (see
below). Thus, it will be important to determine the B cell-intrinsic
versus -extrinsic requirements for TLR gene expression. In any
case, the fact that anti-chromatin Abs stimulate extrafollicular
responses by AM14 RF B cells in vivo and that AM14 B cell stim-
ulation in vitro requires MyD88 suggests that TLR-dependent
signals could direct extrafollicular responses in vivo. This bears
further in vivo investigation in part because the in vitro cultures
resulted only in proliferation and not differentiation.
Conversely, the reliance on TLR signals, along with the fact
that T cell-independent responses occur at extrafollicular sites
(MacLennan et al., 2003), raises the question of how T cells influ-
ence this type of autoantibody response. There is reason to think
T cells should be critical: the importance of bidirectional T-B
interactions in lupus and other autoimmune diseases is well
documented (Chan et al., 1999b); B cells undergo mutation,
which is thought to depend on T cells; and T cells can be seen
in contact with activated and dividing RF B cells in AM14
MRL.Faslpr mice (Wang and Shlomchik, 1999; William et al.,
2002). However, there are reasons to question the role of T cells:
there is no obvious T cell epitope on IgG2a anti-chromatin Abs,
yet even in BALB/c mice, chromatin Abs elicit a robust extrafol-
licular RF response within 7 days, suggesting that an Ag-specific
T cell response may be dispensable (Herlands et al., 2007); TLR
signals can induce activation-induced cytidine deaminase di-
rectly in B cells, leading to isotype switch and possibly somatic
hypermutation (Jegerlehner et al., 2007), which would substitute
for signals previously thought to require T cells; and many RF B
cells are not in contact with T cells in the extrafollicular reaction
(William et al., 2002, 2005b).
In the case of clonally ignorant B cells, the extrafollicular re-
sponse could proceed independently of T cells, as long as TLR
and BCR signals are provided by the autoantigen. In the case
of anergic B cells, T cell help may be more important. The re-
sponsiveness of anergic B cells to TLR signals such as LPS is
controversial (Goodnow, 1992; Noorchashm et al., 1999); nota-
bly, anti-DNA anergic B cells do not respond well to LPS. Given
this, and that anergic B cells do not respond to BCR stimuli, it is
reasonable to suspect that the combination of BCR and TLR sig-
nals may not be sufficient to break anergic B cell tolerance. In-
deed, anergic HEL-specific B cells display a split tolerance
upon BCR and TLR ligation, proliferating but failing to produce
AFCs (Rui et al., 2003). However, signals that simulate T cell
help, in particular CD40 ligation and IL-4, do activate anergic B
cells (Cooke et al., 1994). Indeed, if provided strong T cell help,
anti-DNA B cells are induced to proliferate and differentiate
along both the GC and the extrafollicular pathways (Seo et al.,
2002). Similarly, anergic B cells can be activated in vivo by strong
T cell help when the constitutive low-level tolerizing BCR signal is
replaced with a more immunogenic form of Ag (Cooke et al.,
1994; Goodnow et al., 1991).
In addition to T cell and TLR signals, there are other factors
and cell types that influence the generation of autoantibodies.24 Immunity 28, January 2008 ª2008 Elsevier Inc.These include: BAFF and a proliferation-inducing ligand (APRIL)
(Schneider, 2005); type I IFN, which has direct and indirect im-
pacts on B cells (Coro et al., 2006; Le Bon et al., 2001); and
DCs, which capture ICs and secrete cytokines including BAFF,
APRIL, and IFN-I (Boule et al., 2004; Schneider, 2005). It is highly
likely that both T cells and TLR signals contribute to and direct
autoantibody responses; however, more work is needed to un-
derstand how these and other signals precisely direct the onset
and nature of autoreactive B cell responses.
Implications for Understanding Disease Pathogenesis
and Designing Therapy
Figure 2 depicts the contrasting stimulatory requirements, mo-
lecular and cellular interactions, and outcomes of the extrafollic-
ular versus the GC pathway of stimulating autoreactive B cells.
Different signals and cell types may be required at each site.
For example, conventional DCs are prominent at extrafollicular
sites whereas stromal follicular dendritic cells are exclusively
found in the GC. Interventions that affect key molecules like
BAFF or IFN-I could have differential effects on the two types
of response. Similarly, if it is true that strong TLR signals promote
the extrafollicular response, then TLR inhibitors may selectively
affect this pathway. It has been suggested that because somatic
mutations could create de novo self-reactivity, self-tolerance
mechanisms should exist in the GC, and there is some evidence
for this (Han et al., 1995; Hande et al., 1998; Pulendran et al.,
1995); we have speculated that ICs trapped in the GC contribute
to tolerance rather than activation (Haberman and Shlomchik,
2003). We have also suggested that B cell activation outside of
GCs may not be subject to self-tolerance mechanisms that
would filter out high-affinity self-reactive cells generated in
GCs (William et al., 2002).
Although it seems likely that the GC pathway could generate
autoreactive memory cells, whether autoreactive B cells stimu-
lated via the extrafollicular pathway can generate memory is
unknown. Memory cells could serve as a reservoir of autoreac-
tive cells that are easier to reactivate (Tangye et al., 2003), which
in turn could contribute to chronicity and refractoriness to ther-
apy (Jacobi et al., 2003; Manz et al., 2006).
Insights about the nature of the extrafollicular response can
also help to explain results of clinical trials of B cell depletion
with anti-CD20 in RA and SLE. Certain autoantibodies, notably
anti-DNA and RF, decayed rapidly after treatment (Cambridge
et al., 2003; Sfikakis et al., 2005), although AFCs lack CD20
and are not directly depleted (Ahuja et al., 2007; Jacobi et al.,
2003). Therefore, these autoantibodies were being generated
from rapidly renewing CD20+ precursors, most consistent with
the short-lived plasmablast pathway. On the other hand, anti-
Sm Abs were generally found to decay slowly, if at all, more con-
sistent with their generation via the GC pathway (Cambridge
et al., 2006). This is one illustration of how the concepts and
information derived frommurine studies can help in understand-
ing therapeutic approaches and studies.
Conclusion
There are many facets to B cell tolerance and how this breaks
down in autoimmune diseases. Central and peripheral mecha-
nisms like deletion, receptor editing, and anergy all shape the
responsive B cell repertoire. Moreover, it is clear that some
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quiescent in normal individuals. Environmental and genetic fac-
tors in certain individuals can lead to the aberrant activation of
some or all of these types of autoreactive B cells, and if this is
not controlled, B cell-dependent autoimmune diseasewill ensue.
This activation, which is likely influenced by T cells and con-
trolled by TLRs, can take place at extrafollicular sites in the
spleen, leading to robust generation of short-lived plasmablasts.
Thus, the autoantibody response, though chronic in terms of the
individual, is actually a dynamic and ongoing process. This
dynamic response could explain why a number of autoimmune
diseases are rapidly responsive to therapies that target B cells.
Further elucidation of how autoreactive B cells are regulated
and activated and why certain autoantigens uniquely direct the
nature of the response will advance basic knowledge of the
disregulated immune response as well as enhance design of
therapies for diseases in patients suffering from SLE and related
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